CLINICAL TRIALS ARTICLES

• From Promise To Precision: Defining The Therapeutic Niche for mRNA

  CureVac CEO Alexander Zehnder shares his thoughts/visions on how mRNA neoantigen vaccines could become even more revolutionary for patient populations in the future. Though it may be early days, this conversation is a great case study for how RNA companies are striving to keep both scientific and commercial market opportunities top of mind from the earliest days of development.

• The Marriage of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions

  Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?

• Top 5 mRNA/RNA Developments of 2024 (Part 1)

  In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024.

• "The Ghost Of mRNA's Future": 2025 Outlook From RNA Leaders

  As the Charles Dickens fans among us already know, there is still one pretty important “ghost” that has yet to be channeled on this “hallowed” page, and that’s the “Ghost of mRNA/RNA Innovations Yet To Come.” (Yes. That’s a thing.) Here, I share several future-facing “visions” from the conversations I had with five RNA leaders.

• "Ghosts Of mRNA Past & Present": 6 RNA/LNP Execs Revisit 2024

  But much like Dicken's “A Christmas Carol” with its emphasis on how the past and present inform the future, I was struck by six RNA executive’s appreciation for where we have been and currently are as an industry, and how these moments in time are already informing mRNA/RNA’s bright future.

• Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases

  EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.